The FDA has pulled Teva Pharmaceuticals' (TEVA 0.91%) generic version of antidepressant drug Wellbutrin from the market. The issue is not one of safety, but efficacy, as Teva's 300mg generic fails to meet the bioequivalence of the original branded version, which is marketed by Valent Pharamaceuticals (BHC 20.36%). The 150mg dosage of the drug performs as required and will not be affected.
If instances like this lead the FDA to reassess the generic approval process, it would be good news for branded pharma, in general, and bad news for generics. Raising the hurdle for generic bioequivalence could mean discount-drug cost spikes down the line. For the full story and Fool.com analyst Brenton Flynn's take on the issue, check out the video below.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.